Nov 28, 2012 | Coding, Billing, and Collections, Compliance, Legal, and Malpractice, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Uncategorized
Unexpected opposition to EHR incentive program should be watched by pathologists and clinical laboratory managers Questions about the value of the federal government’s program to encourage provider adoption of electronic health record (EHR) systems were raised by Republican leaders in both houses of Congress just weeks before the election on November 6. Because clinical laboratories and pathology groups have a big stake in interfacing their laboratory information systems to physicians’ EHRs,...
Feb 20, 2012 | Laboratory News, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement
A part of this legislation, the grandfather clause on Technical Component (TC) anatomic pathology services was extended through June 1, 2012. Last Friday, clinical laboratories got bad news about new cuts to the Medicare Part B medical laboratory test fee schedule. Congress voted on a temporary funding fix to keep Medicare physician fees at current levels for 10 more months and a reduction in lab test fees was one source of the money that Congress used to fund this bill. Pathologists and...
Oct 19, 2011 | Compliance, Legal, and Malpractice, Laboratory News, Laboratory Pathology
Nation’s clinical laboratories may see significant reductions in federal funding for medical laboratory tests in the 2012 federal budget Unprecedented cuts in funding for clinical laboratory services are expected from Congress in coming months. That’s because federal legislators need deep cuts from many sources to cope with the current budget crisis. It is also why some Beltway insiders predict that fees for medical laboratory testing will be substantially reduced. Although many lab industry...
Aug 27, 2010 | Laboratory Management and Operations, Laboratory Pathology, Management & Operations
GAO Gives Congress a Poor Report on Direct-to-Consumer Genetic Tests Sold by Web-Based Companies According to the Wall Street Journal, Direct-to-consumer (DTC) genetic tests from the four companies 23andMe, Navigenics, deCODE genetics, and Pathway Genomics Corp, are generating results “that are misleading and of little or no practical use.” This was the finding of the U.S. General Accounting Office (GAO) in its recently released report. Pathologists and clinical laboratory managers will be...
Jan 22, 2010 | Laboratory News, Laboratory Pathology
Pathologists and clinical laboratories can expect a new type of federal oversight One consequence following passage of the massive health bill now being considered by Congress is a significant expansion in the role of the Internal Revenue Service for certain healthcare activities. So writes Phil Galewitz and Christopher Weaver of Kaiser Health News about developments that are not auspicious for pathology and clinical laboratory testing. They note that the job of enforcing the legislative...
